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1. Introduction 
Monocytes are essential components of the innate immune system responsible for 
phagocytosis of pathogens, dead cells, and anti-tumor activities. These cells are involved in 
a remarkably diverse array of homeostatic processes ranging from host defense to tissue 
turnover and are emerging as key players in the pathophysiology of several diseases 
including atherosclerosis, arthritis, obesity, autoimmunity, and cancer. These mononuclear 
blood cells respond to “self” and “non-self” stimulatory signals by mediating immune 
responses, controlling inflammatory cytokines, and accumulating at sites of “danger”. Thus, 
monocytes play a critical role in the protection against invaders. In the case of invader 
“tumors”, monocyte accumulation has been shown to promote neoangiogenesis and tumor 
progression. This paradoxical role of monocytes in normal and tumor development may 
result in the polarized expression of either pro- or anti-tumor functions. Recognition of 
diverse monocyte subsets helps explain the plethora of functions attributed to monocytes in 
acute and chronic inflammatory diseases. Microenvironmental signals, to which monocytes 
are exposed, play a key role in the setting of their phenotype selectively tuning their 
functions. In the tumor microenvironment, recruitment of selected monocyte subsets and 
the inhibition of the apoptotic program promote increase numbers of macrophages in the 
tumor. A complex network of differentiation factors and inflammatory stimuli determine 
monocyte life span by blocking the apoptotic pathway and activating a myriad of survival 
pathways. The present chapter will discuss molecular changes that dictate the fate and 
behavior of monocyte subsets contributing to tumor biology. In addition, we will discuss the 
antagonistic and synergistic interplay of transcriptional and posttranscriptional regulatory 
networks that contribute to the specification of monocytic cell fate and their contribution in 
tumor progression. The recognition of these molecular networks will furnish strategies to 
decrease monocytic cell recruitment, survival at the tumor sites, and facilitate monocytic 
“re-education” programs reestablishing their normal anti-tumor function helping to define 
novel therapeutic strategy against cancer and other inflammatory diseases.  
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2. Monocyte subsets: Molecular and functional heterogeneity 
Heterogeneous populations of monocytes originate from common myeloid precursor cells 
and are responsible for controlling inflammation, tissue repair, stimulating angiogenesis, 
tumor progression, and growth. These populations are dynamic, capable to adapt their 
identity, fate, and immunological function in response to environmental cues. Monocytes 
help to neutralize self or non-self danger signals through innate mechanisms. In this 
defensive reaction, the blood and lymphatic vascular system are essential partners. In 
addition, recruitment of monocytic cells leads to new blood vessel formation or 
angiogenesis, a central feature of tumor growth. Monocytes act as defenders, secreting 
cytokines and in turn modulate other cells of the innate and adaptive immune system trying 
to combat the tumor. Interestingly, cues from the tumor microenvironment promote 
changes in monocytic cells fate and immune function leading to changes in myelogenous 
populations that ensure tumor growth and metastasis, in a co-adaptation process yet not 
well understood.  
The tumor microenvironment is a complex milieu composed of cellular and noncellular 
(matrix) components. Myeloid cells, among others monocytes/macrophages, constitute 
about 50% of the infiltrating cells (Pollard, 2004). The origins and identities of tumor 
infiltrating myeloid cells have been recently uncovered as technical advances helped 
identify these heterogeneous subsets.  
Circulating human and mouse monocytes are broadly classified on the basis of surface 
receptor markers and biological responses into three subtypes. Based on the recently 
approved nomenclature by the Nomenclature Committee of the International Union of 
Immunological Societies (Ziegler-Heitbrock et al., 2010) human monocyte subtypes are 
categorized into “classical” expressing high levels of CD14 and lacking CD16 expression 
(CD14++CD16- or CD16-) constituting 90% of the population and the remaining 10% 
expressing CD14 and CD16 or FcIII receptor (CD14+CD16+). The latest group is further 
subdivided based on the level of CD14 and CD16 expression into “intermediate” 
(CD14++CD16+ or CD16+) and “non-classical” (CD14+CD16++ or CD16++) (Parihar et al., 2010; 
Ziegler-Heitbrock et al., 2010) (Fig. 1). The mouse circulating monocyte counterparts are 
classified into three types based on the expression of the surface glycoprotein Ly6C and the 
transmembrane sialoglycoprotein CD43. These are “classical: Ly6C++CD43+, “intermediate”: 
Ly6C++CD43++ and “non-classical”: Ly6C+CD43++ monocytes (Ziegler-Heitbrock et al., 2010). 
Ly6C is part of the epitope of granulocyte differentiation antigen-1 (Gr-1), also recognized 
by Gr-1 antibodies (Hanninen et al., 1997). Hence, Ly6C++ (Ly6Chigh) monocytes are Gr-1+ 
and Ly6C+ (Ly6Clow) are Gr-1- (Geissmann et al., 2010). Classical mouse monocytes (Ly6Chigh 
CD43+) express CCR2+ and CD62L+ and low levels of the chemokine receptor CX3CR1low, 
whereas non-classical (LY6ClowCD43++) are CX3CR1high but CCR2−CD62L− (Auffray et al., 
2009). Recently, closer association has been shown between the human classical, 
intermediate, and mouse Ly6Chigh, irrespective of CD16 expression while the Ly6Clow 
correspond to non-classical CD14lowCD16++ monocytes (Cros et al., 2010) (Fig. 1). 
Several types of myeloid cells are important components of the tumor stroma contributing 
to diverse tumor-promoting activities including Tumor-Infiltrating Monocytes (TIM) and 
Tumor-Associated Macrophages (TAM) (Hanahan & Weinberg, 2011) (Fig. 1). Circulating  
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Fig. 1. Role of monocytes and macrophages in tumor progression. Heterogeneous monocyte 
populations arising from a common precursor have been described. Different monocyte 
subsets contribute to the infiltration of myelogenous cells such as TIM, TEM, and TAM into 
the tumor, which in paracrine and autocrine manner contribute to angiogenesis, tumor 
progression, and growth. Plastic behavior of TAMs from M1 to M2 as well as other 
infiltrated monocytes is characterized by distinct cytokine and chemokine profiles 
promoting an anti-tumoral or immunosuppressive environment respectively co-adapting to 
the tumor microenvironment.  
monocytes expressing Tie-2 [angiopoietin-2 (Ang-2)] named TEM, comprised within 
CD14+CD16++ human monocytes and mice Ly6C+ (Ly6Clow) are recruited to the tumor where 
they have been shown to be essential for angiogenesis (Venneri et al., 2007). In a mammary 
adenocarcinoma tumor model the majority of tumor infiltrating monocytes differentiating 
into TAM were Ly6C++ (Movahedi et al., 2010). The tumor environment not only attracts 
myeloid cells but also modulates their fate resulting in a shift in hematopoiesis leading to an 
increase in myeloid cell accumulation in bone marrow, blood, spleen, and at the tumor site 
(Almand et al., 2001; Bronte et al., 2000; Mantovani et al., 2008). 
Monocyte recruitment to the tumor site is greatly influenced by several factors. Among 
others, the prototype CC chemokine MCP-1 (monocyte chemoattractant protein-1; also 
known as CCL2) secreted by malignant cells increases monocyte infiltration (Gu et al., 1999). 
Significantly higher levels of MCP-1 have been reported in patients with primary ovarian 
cancer and melanoma (Negus et al., 1995) and MCP-1 down-regulation decreased monocyte 
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migration in ovarian cancer (Negus et al., 1998). Other chemokines and growth factors such 
as placental growth factor (PGF), TGF-ǃ, PGE-2, CCL3 (MIP-1ǂ), CCL4 (MIP-1ǃ), RANTES 
(also known as CCL-5), and M-CSF, are found at high levels in tumors and contribute to the 
recruitment, survival, and differentiation of monocytes into the tumor (Fig. 1). High M-CSF 
expression is related with TAMs accumulation in breast carcinomas (Tang et al., 1992). 
Vascular endothelial growth factor (VEGF) is also involved in monocyte recruitment into 
tumors (Dineen et al., 2008; Murdoch et al., 2008). Elevated levels of RANTES were reported 
in ovarian cancer  and breast cancer contributed to cancer progression and monocytes 
recruitment (Azenshtein et al., 2002; Negus et al., 1997). 
Thus, secreted factors by tumor-infiltrating monocytes and tumor cells help modulate tumor 
growth and monocyte infiltration and fate determination contributing to tumor growth and 
progression.  
3. Monocytic transcriptomes 
In recent years the improvement in cell isolation techniques has allowed great advances in 
the understanding of transcriptomes in circulating monocytes helping identify unique 
signatures for different monocyte subsets and share remarkably transcriptional similarity 
(Ancuta et al., 2009; Mobley et al., 2007; Zhao et al., 2009). Genome wide studies on 
monocytes transcriptomes suggest that both CD16- and CD16+ monocytes share a common 
precursor (Ancuta et al., 2009). Despite the high similarity on expression profiles, differences 
relate to genes corresponding to cell-cell adhesion, trafficking, inflammation and immune 
responses, cell cycle, signal trasnduction and proliferation. Strict statistical analysis 
indicated as few as ~ 60 differentially expressed genes between monocyte subsets (Ancuta et 
al., 2009). 
Classical monocytes (CD14+CD16-) have higher expression of genes involved in adhesion 
such as CCR2, CD62L and CD11b. In addition, the genes related to inflammation, 
angiogenesis and wound healing are also highly expressed in classical monocytes, revealing 
its implication in tissue repair (Wong et al., 2011). These classical monocytes also  express 
higher level of CD14 and the cytokine IL-8 (Mobley et al., 2007). In these monocytes  all 
phagocytosis enhancing proteins were highly expressed including levels of CD93, the 
receptor for complement component C1q1 (C1q1R), a component of a larger receptor 
complex for C1q complement factor and mannose-binding lectin (MBL2) (Ancuta et al., 
2009). Furthermore, classical monocytes also showed high level expression of 
proinflammatory molecules such as S100A12, S100A9, S1008, and were among the top 50 
most highly expressed genes (Wong et al., 2011). 
CD16+ subsets possess a more differentiated profile with increased expression of 
macrophage and dendritic cell-like genes, probably indicating a more advanced stage of 
differentiation of these cells (Ancuta et al., 2009). These cells express high levels of genes 
involved in antigen processing, antimicrobial activity and host defense. High expression 
of genes encoding defensins, lysosomal proteases including cathepsins and elastase have 
been found (Mobley et al., 2007). Intermediate monocytes (CD14++ CD16+) showed 
enrichment for genes under major histocompatibility complex (MHC) class II processing 
and presenting, these genes mainly includes CD47, HLA-DO and CD40. MARCO 
(macrophage receptor with collagenous structure) is also one of the highly expressed gene 
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in the intermediate subset of monocytes (Wong et al., 2011). CD16+ monocytes express 
higher levels of TNF- and chemokine receptor CX3CR1, CX3CR2 and colony-stimulating 
factor 1 receptor (CSF1R), the receptor for macrophage colony-stimulating factor (M-CSF) 
than classical CD16- monocytes (Ancuta et al., 2009; Wong et al., 2011; Zhao et al., 2009). 
Proteomic analysis also showed small differences with only 235 proteins differentially 
expressed between the monocyte subsets (Martinez, 2009). In addition to CD16, higher 
expression of the hematopoietic cell kinase (HCK) and the tyrosine protein kinase (LYN) 
were observed (Zhao et al., 2009). Interestingly the nonclassical monocytes (CD16++) 
showed the gene enrichment in the category of cytoskeleton rearrangement and 
phagocytosis. Genes related to phagocytosis such as LYN, HCK, ITAM of FCRs, C1QA, 
C1QB and also SLAN were found highly expressed in nonclassical monocytes (Wong et 
al., 2011). In pathological conditions, monocyte functions are finely tuned by the 
microenvironment. In this regard, hypoxic conditions found in tumors affect gene 
expression. Transcriptome analysis of hypoxic primary human monocytes revealed 
modulation of a significant cluster of genes with immunological relevance (Bosco et al., 
2006). These included scavenger receptors: CD163, also found highly upregulated in 
CD16- subsets as well as MARCO , stabilin-1 (STAB1), macrophage scavenger receptor-1 
(MSR1) (Mobley et al., 2007). Toll like receptor-7 (TLR7), immunoregulatory, 
costimulatory, and adhesion molecules: CD32, CD64, CD69, CD89, leukocyte membrane 
Ag (CMRF-35H), integrin ǃ-5 (ITGB5), chemokines/cytokines receptors (CCL23, CCL15, 
CCL8, CCR1, CCR2, RDC1, IL-23A, IL-6ST) were also highly expressed under hypoxia 
(Bosco et al., 2006). Hypoxia also controlled gene expression of chemokine receptors 
including CXCL1, CXCL8, CCL3, CXCR4 (Murdoch et al., 2004). 
Transcriptome studies are unraveling the complexities of the monocyte populations and 
provide evidence of the specialized function of specific subsets. High expression of IL-8 and 
adhesion molecules in CD16- subsets seem to support the role as inflammatory, capable to 
leave the circulation and infiltrate. In addition, high expression of M-CSF in CD16+ support 
their role in driving differentiation of CD16-, a more immature pool that could replenish 
macropahges at inflammatory sites. Studies in gene expression profiles in human monocyte 
subpopulations as part of tumor biology remain scarce and future studies in this area will 
thereby help to understand their specific roles as well as define future approaches to re-
educate monocytes in the tumor microenvironment.  
4. Role of monocyte subsets in tumor progression  
4.1 Monocyte deactivation  
It has been widely accepted that cancer progression is an inherently proinflammatory 
process that involves the activation of the innate and adaptive immune system. During 
tumorigenesis, monocytes are destined to give anti-tumor response of the host and act both 
as cells presenting tumor-associated antigens to tumor-infiltrating lymphocytes and as 
cytotoxic effector cells (Mytar et al., 2003). However, cancer cells have developed 
mechanisms that inhibit immune surveillance (Pardoll, 2003), characterized by the impaired 
ability of monocytes to produce IFN-, TNF-ǂ, IL-12, while enhance IL-10 secretion. IL-10 is 
immunosuppressive, tumor promoting, and inhibits the production of IL-2, IFNǄ, IL-12, 
TNF-ǂ, resulting in a reduced Th1 response (Sica et al., 2006). Different studies have 
reported increased IL-10 serum levels in patients with melanoma and other solid tumors 
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(Fortis et al., 1996; Sato et al., 1996). IL-12 plays central role in activating anti-tumor 
immunity by stimulating the production of IFN- and TNF-ǂ necessary for cytotoxic effects. 
In many cancers, for instance in colorectal cancer reduced production of IL-12 was 
accompanied by increased production of IL-10 (O'Hara et al., 1998). Deactivation of 
monocytes can be reversed with Bovis bacillus Calmette-Guerin (BCG), the prototype 
immunomodulator, which inhibits IL-10 production, thus reversing monocyte deactivation 
(Baran et al., 2004).  
Deactivation of TIM is also mediated by other mechanisms. Hyaluronan (HA), an important 
tumor microenvironment matrix structure, produced by tumor cells, is now emerging as a 
key factor in monocyte deactivation and tumor progression (Mytar et al., 2003; Toole, 2004). 
Ligation of CD44 by HA is a proinflammatory event that regulates monocyte adhesion and 
cytokine production and was found to stimulate the expression of IRAK (IL-1 receptor-
associated kinase)-M. High levels of IRAK-M were reported in patients of chronic myeloid 
leukemia and metastasis (del Fresno et al., 2005). Co-culture experiments of CD14+ 
monocytes with a variety of tumor cells show that tumor cells express high level of 
prostaglandin (PG) that also contributes to the downregulation of TNF-ǂ, IL-12, IRAK-1 
interrupting the inflammatory response against cancer progression. These findings strongly 
suggest that the functional activity of monocytes is adversely modified by the local tumor 
microenvironment. Notably, the deactivation mechanisms of monocyte in cancer may not 
just be limited to tumor microenvironment but also players in other inflammatory diseases 
such as atherosclerosis, arthritis, and obesity.  
4.2 Angiogenesis  
Once the tumor cells escape recognition and destruction by infiltrating monocyte, these 
infiltrating cells participate in tumor growth by promoting angiogenesis (Lin et al., 2001), 
an essential process in the tumor progression and growth. High numbers of human 
vascular leukocytes found in human ovarian cancer have been suggested to form 
neovessels in mouse xenotransplantations (Conejo-Garcia et al., 2005). Gr-1+ monocytes 
promote angiogenesis via paracrine mechanisms (Yang et al., 2004). Vascular leukocytes, a 
subset of CD11C+ MHC-II+ dendritic-cell precursors expressing endothelial vascular 
markers VE-cadherin, CD34, and CD146 also contribute to tumor angiogenesis (Conejo-
Garcia et al., 2005; Yang et al., 2004). Circulating TEM derived from non-classical 
monocytes contributes to tumor angiogenesis, migrating towards Ang-2, released at high 
levels by activated endothelial cells and angiogenic vessels at tumor sites (Venneri et al., 
2007). Ang-2 also inhibits TNF-ǂ release (Lewis et al., 2007; Murdoch et al., 2007), 
normally responsible for promoting apoptosis of both tumor and endothelial cells 
(Petrache et al., 2001). Hence, Ang-2-mediated down-regulation of TNF-ǂ may increase 
metastasis and angiogenesis contributing to tumor growth. The molecular basis of factors 
that render proangiogenic activity in TEM are still not well understood. But elimination of 
TEMs in mouse glioma models was shown to reduce tumor growth and vascularity (De 
Palma et al., 2005), supporting the role of TEM in tumor blood vessels formation. In 
human tumor models, CD14+ TIM monocytes can develop endothelial phenotype 
(Schmeisser et al., 2001) and actively participate in neovascularization during tumor 
growth (Urbich et al., 2003).  
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Recent studies indicated that CCL2 synthesized by metastatic tumor cells and by the target-
site tissue stroma is critical for the recruitment of CCR2-expressing monocyte subsets. 
Activation of the CCL2-CCR2 signaling axis promotes extravasation and recruitment of 
inflammatory monocyte subsets into metastatic tumor sites and helps promote 
differentiation of these monoyctes into non-proliferating TAMs (Qian et al., 2011). 
Transcriptome studies in both resident and inflammatory monocytes show higher 
expression of VegfA, a potent angiogenic factor in inflammatory monocytes CD14+CD16- 
subsets, recruited in large numbers to metastatic areas (Qian et al., 2011). Future 
comprehensive trsancriptome analysis in purified monocyte populations under 
pathophysiological conditions should be helpful to gain a further understanding of the 
functional roles of different monocyte populations in tumor progression. 
5. Regulation of monocyte subsets  
5.1 Regulation of survival and cell death of monocytes in tumors 
A complex network of survival and apoptotic pathways determines monocyte fate. Several 
kinases, transcription factors and anti- and pro-apoptotic proteins play key roles in 
determining monocyte survival and cell death. All circulating monocyte subsets have very 
short life span of just few days (Fahy et al., 1999; Zeigler et al., 2003). Inflammatory and 
differentiation stimuli are known to halt apoptosis and inducing prolonged monocyte 
survival. Among others M-CSF, TNF-, and IL-1 promote survival by deactivating the 
apoptotic program lead by caspases (Fahy et al., 1999; Goyal et al., 2002; Kelley et al., 1999). 
The tumor microenvironment characterized by alterations in cytokine, chemokine, and 
growth factor expression contributes to mediate prolonged monocyte survival (Zou, 2005). 
In fact, increase levels of TGF-ǃ, IL-10, and VEGF alter TIM and TEM from anti-tumoral to 
immunosuppressor and proangiogenic in part by switching their cytokine and growth 
factors expressions (Whiteside, 2008) (Fig. 1).  
Among the signaling molecules involved in activation and survival, the phosphatidylinositol 
3-kinase (PI3K)-AKT axis has a central role in regulating a multitude of essential myelogenous 
events, such as differentiation, phagocytosis, oxidative burst, and TLR-mediated responses 
(Franke et al., 1997; Parihar et al., 2010). PI3K activation was also shown to direct infiltration 
(Funamoto et al., 2002; Wang et al., 2002). M-CSF-induced activation of AKT through 
caspase-9 phosphorylation inhibits apoptosis (Kelley et al., 1999), promoting prolonged 
survival and sustaining the differentiation program (Gonzalez-Mejia & Doseff, 2009). In 
addition, PI3K activates protein kinase C (PKC) in monocytes (Herrera-Velit et al., 1997) 
leading to the induction of the activated mitogen-activated protein kinase (MAPK) pathway 
(Rao, 2001), including the extracellular signal-regulated kinase (ERK), the c-JNK and p38 
which are hubs to multiple networks of survival (Parihar et al., 2010). Pro-inflammatory 
mediators induce the PI3K/AKT and MAPK/ERK pathways that in turn are responsible in 
determining the balance of inflammatory versus anti-inflammatory cytokines.  
In the hypoxic regions of a tumor, activation of PI3K/AKT leads to HIF (hypoxia inducing 
factor)-1 activity which in turn regulates tumor growth, angiogenesis, metastasis, and 
monocytes/macrophages recruitment (Semenza, 2003). While the role of HIF-1 in different 
monocyte subsets and macrophages is not fully understood, increased HIF-1 expression in 
TAMs was found to contribute to tumor angiogenesis and invasiveness (Werno et al., 2010).  
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The transcription factor nuclear factor-κB (NF-κB), plays a critical role in tumor biology 
(Karin & Greten, 2005). While in other cell types NF-κB has various tumor-promoting 
functions, in monocytes the activation of NF-κB results in the release of cytokines, such as 
TNF-ǂ and IL-6 which not only trigger prosurvival signals in tumor cells but also support 
growth and progression, and importantly sustain a dysregulated immune function 
(Hagemann et al., 2009; Pikarsky et al., 2004). Activation of NF-κB leads to increase expression 
of angiogenic factors such as VEGF, CXCL1 and CXCL8  and anti-apoptotic molecules 
including the inhibitor of apoptotic proteins (IAPs), and bcl-2 (Richmond, 2002). The relevance 
of the NF-κB signaling pathway is illustrated in a mouse model of colitis associated cancer, 
where deletion of IKK-ǃ reduced the production of tumor promoting paracrine factors and 
subsequently decreased carcinoma growth (Greten et al., 2004). In hepatocellular carcinomas 
the NF-κB activating kinase IKK-ǃ suppresses early chemically-induced liver tumorigenesis by 
inhibiting hepatocyte death and compensatory proliferation. This anti-tumorigenic activity of 
hepatocyte IKK-ǃ was suggested to be due to the induction of NF-κB-dependent pro-survival 
and anti-oxidant genes (He et al., 2010). Deletion of IKK-ǃ in myeloid cells resulted in a 
significant decrease in tumor size and diminished the expression of proinflammatory 
cytokines that may serve as tumor growth factors (Yoshimura, 2006). 
Caspases, the cysteine proteases central to programmed cell death, including “activators” 
(caspases-1, 2, 8, 9, and 10) and ‘executioners’ (caspases-3, 6, and 7) play fundamental roles 
in myelogenous cells through the activation of the extrinsic and intrinsic apoptotic cascade 
(Riedl & Shi, 2004). Fas receptor-induced apoptosis has a key role in monocyte biology as 
both homozygous FasR deficient (lpr/lpr) and heterozygous FasR and Fas ligand deficient 
(lpr/gld)  mice have increased numbers of inflammatory and resident monocytes resulting in 
splenomegaly, lymphadenopathy, and accumulation of tissue macrophages (Ashkenazi & 
Dixit, 1998; Brown et al., 2004). Cytokines, CCL2 and IL-6 abundant in the tumor 
microenvironment have been shown to inhibit caspase-8 and promote enhanced autophagic 
activity to protect the monocytes recruited to the tumor and, at the same time, induce their 
differentiation toward M2-type macrophages (Roca et al., 2009). Futhermore, M-CSF induces 
caspase-9 inhibition leading to reduce apoptosis (Kelley et al., 1999). Several other inhibitors 
of the apoptotic pathways including members of the Bcl-2 family have been characterized 
(Youle & Strasser, 2008) and XIAP also play a crucial role in cell survival and tumor 
development. XIAP directly inhibits activator caspase-9 and also executioner caspases in 
cancer cells and increase expression of XIAP has been reported in monocyte differentiation 
(Sasaki et al., 2000). However, the role of XIAP in different monocyte subsets has not been 
studied. Our studies identified the small heat shock protein (Hsp27) as a direct inhibitor of 
caspase-3 in monocytes. Notably a significant increase in Hsp27 expression was found to be 
required during monocyte-macrophage differentiation (Voss et al., 2007). Hsp27 is highly 
expressed in several tumors and high levels of Hsp27 in plasma have been associated with 
risk of lung cancer  (Wang et al., 2010). Hsp27 was found to have functions in IL-1-induced 
cell signaling and pro-inflammatory gene expression suggesting its ability to modulate 
immunity (Alford et al., 2007). Whether the expression of apoptosis inhibitors such as Hsp27 
is altered in TIM and TAMs have yet to be studied. These findings suggest that anti-
apoptotic factors in plasma can switch monocyte life span contributing to their 
accumulation into tumors. It is possible to hypothesize that monocyte re-education 
programs could target molecular networks involved in shifting survival and cell death 
programs as well as immunoparalysis in monocytes. 
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5.2 Epigenetics and microRNAs regulation in monocytes and macrophages during 
tumor progression  
During hematopoiesis gradual changes in gene expression orchestrate lineage-specification. 
The myelomonocytic lineage originates from a ganulocyte-erythrocyte-megakaryocyte-
macrophage colony-forming unit (GEMM-CFU) that promotes formation of the GM-CFU or 
ganulocyte-macrophage colony-forming unit. GM-CFU under the control of G-MCSF, M-
CSF and IL-3 regulate the differentiation of this progenitor to a monocyte precursor (M-
CFU) that becomes a promonocyte in the bone marrow. Differentiation of precursor cells is 
controlled by transcription factors that regulate differentation and survival. A combination 
of transcription factors including GATA-2, GATA-1, SCL, and members of the homeobox 
proteins (HOXB) control monocyte survival. Repression of GATA-1, SCL, and c-Myc 
expression allows monocytic differentiation (Valledor et al., 1998). Earliest stages of myeloid 
lineage specification involve the activity of Runt-related transcription factor 1 (RUNX1). One 
of the main targets of RUNX1 is PU.1, a member of the ETS (E-twenty six) family 
transcription factor (Olson et al., 1995). PU.1 is key in differentiation by controlling the 
expression of M-CSF and GM-CSF receptors. In addition, PU.1 regulates expression of FC 
receptors involved in phagocytosis. Thus, PU.1 has a critical role in monocytic 
differentiation by regulating expression of molecules essential for differentiation and 
function of monocytic lineages. Intermediate stages of differentiation are regulated among 
others by transcription factor CCAAT enhancer-binding protein (C/EBP) members, c-Myc 
and HOXB7, the latest induced by GM-CSF (Friedman, 2002; Yeamans et al., 2007). In 
addition, c-Jun dimmers (AP-1)  and STAT members contribute to the induction of 
monocytic genes (Friedman, 2002). STAT3 is one of the important transcription factors that 
play an essential role in cell survival, proliferation, and differentiation. Classical monocytes, 
express high levels of AP-1-axis regulated genes, and it has been suggested that this gene 
repertoire may be responsible for the plastic behavior of this monocyte subset to recognize 
self and non-self stimuli (Wong et al., 2011). In non-classical subsets transcription factors 
controlling apoptosis, differentiation, and proliferation were highly expressed, among them 
E2F1, ETS1, and FOXO1, well known to regulate proliferation. Intermediate monocyte 
subsets showed reciprocal increases in transcription factors found in both classical and non-
classical subsets (Wong et al., 2011). 
Epigenetic changes regulated by histone-modifying enzymes such as histone 
acetyltransferases (HATs), histone deacetylases (HDAC), and methylases provide additional 
regulatory mechanisms for monocytic gene expression. Abnormal activity of these enzymes 
leads to changes in gene expression affecting differentiation and apoptosis and causing 
neoplasia and other diseases (Haberland et al., 2009). Acetylation of NF-B induces 
modifications in a temporal manner leading to recruitment of other co-activator and re-
modeling complexes and the induction of inflammatory gene expression (Ito et al., 2000; Lee et 
al., 2006). In monocytes, histone acetylation of the TNF-ǂ promoter has been shown to be 
developmentally regulated and is required for TNF-ǂ expression during acute inflammation 
(Lee et al., 2003). Changes in acetylation of the Decoy Receptor 3 (DcR3) promoter, a member 
of the TNF receptor superfamily, has been reported in tumors affecting expression of MHC 
class II (MHC-II)-dependent antigen presentation (Chang et al., 2008). Recent studies found 
distinct DNA methylation profiles in CD34+ hematopoietic progenitor cells and differentiated 
myeloid cells with pronounced DNA hypomethylation in monocytes (Bocker et al., 2011). 
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Interestingly, age-related methylation changes in CD34+ cells were found. Older progenitor 
cells showed a bimodal pattern with hypomethylation of differentiation associated genes 
and de novo methylation events resembling epigenetic mutations, thus providing an 
important insight into the methylation dynamics during differentiation and suggest that 
epigenetic changes contribute to hematopoietic progenitor cell aging (Bocker et al., 2011). 
Induction of inflammatory genes IL-6, IL-8 and IL-12 were found to depend on HAT/HDAC 
activity (Lu et al., 2005; Schmeck et al., 2008). Treatment of monocytic leukemia cell lines and 
patient samples with demethylating and HDAC inhibitors induced reversion to gene profiles 
found in normal subjects, highlighting the role of chromatin remodeling in monocyte behavior 
(Serrano et al., 2008). Treatment of macrophages with broad-spectrum HDACs inhibitors 
showed anti- and pro-inflammatory effects, HDACs suppressed LPS-induced expression of 
the pro-inflammatory MCP-3, and IL-12 but amplified the expression of the pro-atherogenic 
factors Cox-2 (Halili et al., 2010). Dietary compounds with HDAC inhibitory activities, 
including garcinol, curcumin, and anacardic acid, modulate epigenetic status and are being 
investigated as potential anti-cancer agents (Bolden et al., 2006; Inoue et al., 2004). It will be of 
interest to evaluate how these therapies influence monocytes epigenomes. Future studies to 
evaluate the epigenetic dynamics of monocyte subsets will be of great value to further 
understand their unique functional contributions.  
MicroRNAs (miRNAs) are small non-coding RNAs emerging as new post-trancriptional 
regulators and have been found to contribute in several monocyte functions. The overall 
relevance of miRNA in hematopoiesis has been discussed in detail elsewhere (Baltimore et al., 
2008). Based on the epidemiological studies inflammation contributes to 25% of all cancers by 
increasing cancer risk and cancer development (Mantovani et al., 2008). Several miRNAs were 
found to be elevated in inflammation and cancer. In particular, miRNA-155, miRNA-125b, and 
miRNA-21 have emerged as important miRNAs regulating immune responses. MiRNA-155 is 
elevated in leukemia and lymphoma and transgenic mice overexpressing miRNA-155 in B 
cells, develop B-cell leukemia and sustained expression of miRNA-155 in hematopoietic stem 
cells causes myeloproliferative disorders (O'Connell et al., 2008). MiRNA-155 targets among 
others suppressors of cytokine signaling (SOCS1) and SH2-domain-containing inositol-5-
phosphatase 1 (SHIP-1), both negative regulators of TLR signaling in monocyte/macrophage 
inflammatory response. Recent studies showed that tumor environment causes a sustained 
reduction of miRNA-155 in monocytes/macrophages, which in turn activates the C/EBPǃ (He 
et al., 2009). C/EBPǃ, a member of C/EBP family of leucine zipper transcription factors, plays 
pivotal roles in coordinating the expression of a wide variety of genes that control immune 
responses including COX-2 (Li et al., 2007). C/EBPǃ-deficient mice exhibit defects in 
macrophage activation and differentiation (He et al., 2009). Monocytes exposed to tumor 
microenvironment showed C/EBPǃ expression inversely correlated with miR-155 expression 
and it was found that miRNA-155 could suppress the C/EBPǃ. Furthermore, over-expression 
of miRNA-155 significantly attenuated the cytokine production in tumor-activated monocytes 
(He et al., 2009). Expression of miRNA-146 affects downstream TLR signaling molecules such 
IRAK1 and 2 or TNF receptor-associated factor (TRAF) 6, all involved in the activation of the 
NF-B axis (O'Connell et al., 2010). MiRNA-21 and miRNA-125b are also elevated in 
inflammatory conditions and cancer (Esquela-Kerscher & Slack, 2006).  
Recent studies highlighted different miRNAs profile in circulating monocytes when 
compared with dendritic cells or macrophages (Tserel et al., 2011). However, it is presently 
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unknown whether miRNAs expression is altered in different monocytes subsets in normal 
conditions or in tumorigenesis.  
6. Molecular pathways involved in monocyte fate and re-education 
programming  
Reprogramming implies the conversion of a fully differentiated cell type into another cell 
type without pluripotent intermediate and generally achieved by overexpressing key 
transcription-factors (Zhou & Melton, 2008). Recent studies have reported that various cells 
including fibroblasts can be reprogrammed into blood-cell progenitors (Szabo et al., 2010), 
neurons (Vierbuchen et al., 2010), and cardiomyocytes (Ieda et al., 2010), demonstrating the 
ample applicability of this approach for therapeutic uses.  
Myelomonocytic cells re-education programs have been described. TAMs have been 
suggested to be programmed to specific subtypes such as M1 and M2 upon arrival to the 
tumor microenvironment. It has been shown that administration of GM-CSF in murine 
breast cancer models induces soluble VEGFR-1 resulting in the suppression of VEGF and 
angiogenesis (Eubank et al., 2009). Cytokine-dependent reprogramming using IL-12, which 
impacts innate and adaptive immune systems, has proven the most interesting (Trinchieri, 
1995). IL-12 in its soluble or lipid-encapsulated forms injected into tumor-bearing mice 
resulted in a strong cytotoxic anti-tumor response (Hill et al., 2002), suggesting its capability 
to restore normal immune functions. Inflammatory monocytes expressing high levels of the 
chemokine receptor CCR2 but not CD14-CD16+ were found in increased numbers in several 
chronic inflammatory conditions including atherosclerosis and asthma (Parihar et al., 2010). 
Recent studies showed that administration of lipid nanoparticles containing a CCR2-
silencing short interfering RNA in mice, prevents monocyte accumulation at inflammatory 
sites (Leuschner et al., 2011). Ectopic expression of PU.1 in lymphocytes and neural stem 
cells induced transdifferentiation to the myeloid lineage with functional chemotactic and 
immune functions characteristic of monocytes (Forsberg et al., 2010; Laiosa et al., 2006). 
Transcriptome analysis showed that PU. 1 expression affects chromatin remodeling leading 
to epigenetic changes that ensure macrophage specification (Ostuni & Natoli, 2011). These 
monocytes may serve as vehicles to modulate microenvironments with dysregulated 
immunity such as found in the tumor. Hence, alteration of epigenetic dynamics may also be 
a potential approach to alter monocyte re-programming. It is recognized that macrophages 
adapt in response to the microenvironment (referred to other Chapters in this book). Part of 
this adaptation is based on changes in their transcriptomes (Lawrence & Natoli, 2011). 
However, the molecular mechanisms determining macrophage genetic adaptations remain 
mostly unknown. In the case of monocyte subsets similar studies have not yet been 
conducted. Thus, dissecting the genomic determinants in normal and pathophysiological 
conditions of functional distinct monocyte subsets and TEMs will provide possibilities to re-
educate these cells towards an anti-tumor phenotype, re-establishing apoptotic programs or 
halting their extravasation activities.  
7. Conclusion  
Tumor progression is marked by dynamic changes of the tumor microenvironment from 
early neoplastic events to advanced tumor stages. Recruitment of circulating monocytes to 
www.intechopen.com
 
Tumor Microenvironment and Myelomonocytic Cells 
 
54
specific tumor sites contributes to progressive modulation of signaling molecules such as 
chemokines, cytokines, growth factors, and transcription factors. Specific contributions of 
different monocyte subsets to the tumor associated myelogenous populations of TEM, TIM, 
and TAMs are starting to emerge. Advances in understanding the molecular networks 
regulating myelomonocytic cells functions and fate provide opportunities to implement re-
education programs to rehabilitate normal anti-tumor monocyte behavior. These strategies 
should help limiting myelomonocytic cell survival, halting recruitment to tumor sites, and 
increasing cytotoxic functions providing novel approaches for cancer treatment. Advances 
in this area will not be limited to tumor biology but will also impact our understanding of 
other chronic inflammatory diseases.  
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